A study to investigate the effect of fibrogenesis biomarkers in patients with rheumatoid arthritis treated with methotrexate monotherapy or in combination of either tocilizumab, tofacitinib or adalimumab

Trial Profile

A study to investigate the effect of fibrogenesis biomarkers in patients with rheumatoid arthritis treated with methotrexate monotherapy or in combination of either tocilizumab, tofacitinib or adalimumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top